Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
ValGenesis Wraps Up Global ValConnect Innovation Day Series with Hyderabad Event [Yahoo! Finance]
Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript [Seeking Alpha]
Dr. Reddy's Laboratories (NYSE:RDY) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025